Original Article

Folfiri Plus Panitumumab as the First-Line Treatment in Patients with KRAS Wild-Type Metastatic Colorectal Cencer. A Single Center Experience


  • Çağlayan Geredeli

Received Date: 11.12.2017 Accepted Date: 08.02.2018 Eur Arc Med Res 2018;34(2):98-104


FOLFIRI is widely used in clinical practice for mCRC patients. Panitumumab is used in patients with KRAS wild-type mCRC.This study investigated the efficacy and safety of first-line panitumumab plus FOLFIRI for patients with KRAS wild-type mCRC.

Material and Methods:

In our retrospective study, patients with RAS wild-type mCRC were enrolled into the medical oncology department in Okmeydanı Training and Research Hospital, İstanbul, between April 2014 and September 2016.


A total of 47 patients were enrolled. The median age was 60 years old (range of 35-78). Twenty-seven patients were male, and 20 were female. The median follow-up was 16.4 months, and the median PFS was 11.6 months. Median OS was 26 months in patients with KRAS wildtype mCRC. In wild-type KRAS and NRAS, mCRC patients’ median PFS was 14 months, median OS was 27 months, 90.7% for six-month OS, 82.6% for one-year OS, 82.6% for two-year OS, and 66.1% for three-year OS. The most frequent grade 1/2 toxicities were diarrhea (34.1%), acne-like rash (46.7%), and neutropenia (35.1%). The most frequent grade 3/4 toxicities were diarrhea (7.3%), acne-like rash (6.7%), and neutropenia (11.1%).


First-line panitumumab and FOLFIRI was associated with favorable efficacy in patients with RAS WT mCRC and was well tolerated.

Keywords: metastatic colorectal cancer, FOLFİRİ, Panitumumab